Channel Therapeutics CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Pelthos Therapeutics Inc. has secured a $9.0 million Senior Secured Convertible Note from Ligand Pharmaceuticals Incorporated, enhancing its financial position and granting Ligand significant royalty interests.
Pelthos Therapeutics Inc. has filed an amended Schedule 13D, detailing updated beneficial ownership stakes for Ezra Friedberg, Balmoral Financial Group LLC, and Key Recovery Group LLC following a reverse stock split, a merger, and a private investment in public equity (PIPE) financing.
SCHEDULE 13D: Ligand Pharmaceuticals Secures Major Stake in Pelthos Therapeutics Following Strategic Merger and $18M PIPE Financing
Ligand Pharmaceuticals Incorporated has become a significant beneficial owner of Pelthos Therapeutics Inc., holding 49.9% of its common stock, following the completion of a merger and a private investment in public equity (PIPE) financing.